Full Breakdown
Increased Risk of Ischaemic Optic Neuropathy Linked to Wegovy Compared to Ozempic
3/11/2026, 1:44:13 AM
Overview of the Findings
A recent analysis published in the *British Journal of Ophthalmology* has revealed that patients using Wegovy, a glucagon-like peptide-1 (GLP-1) agonist for weight loss, face nearly five times the risk of developing ischaemic optic neuropathy (ION) compared to those using Ozempic, a similar medication for diabetes management. The study, which examined over 30 million adverse event reports submitted to the U.S. Food and Drug Administration (FDA) from December 2017 to December 2024, indicates that men are three times more likely to experience this condition than women.
Key Data and Statistics
The analysis focused on 31,774 reports associated with semaglutide, the active ingredient in Wegovy, Ozempic, and Rybelsus. Of these, 3,070 reports were linked to Wegovy, while 20,608 were attributed to Ozempic. The odds of ION were found to be significantly higher with Wegovy, with an adjusted odds ratio of 4.74 compared to Ozempic. The study also noted that no cases of ION were reported with Rybelsus, likely due to its slower absorption and lower dosage.
Mechanisms and Implications
Researchers suggest that the higher dosage and faster-acting nature of Wegovy may predispose users to optic nerve hypoperfusion, which can lead to ION. The study highlights a potential dose-dependent safety concern that necessitates further investigation to inform prescribing practices and regulatory policies. Dr. Edward Margolin, a co-author of the study, emphasized that the findings warrant urgent prospective evaluation.
Official Statements & Responses
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has issued warnings regarding the risk of ION associated with semaglutide. Dr. Alison Cave, the MHRA chief safety officer, stated that while the risk is low, awareness of potential side effects is essential for timely treatment. A spokesperson for Novo Nordisk, the manufacturer of these medications, reiterated their commitment to patient safety and ongoing monitoring of adverse events, asserting that the overall benefit-risk profile of semaglutide remains favorable.
Criticism & Opposition
Despite the findings, some experts caution against drawing definitive conclusions from the study. Dr. Samantha Mann, a consultant ophthalmologist, noted that the study's reliance on reported side effects does not establish causation or the true prevalence of ION in clinical practice. Furthermore, Dr. Rudrani Banik highlighted the need for prospective studies to address potential confounding factors, such as patient comorbidities and the anatomical predispositions that may influence ION risk.
What's Next
The growing use of anti-obesity medications, particularly in children, raises concerns about the long-term implications of ION and other ocular complications. As the popularity of these drugs increases, further research is essential to clarify the risks and guide clinical practice. The study's authors and commentators agree on the necessity for additional scrutiny and prospective evaluations to ensure patient safety.
Verbatim Quotes
- “These findings highlight a potential dose-dependent safety concern that warrants urgent prospective evaluation to guide prescribing and regulatory policy.” — Dr. Edward Margolin, University of Toronto
- “The risk of Naion in patients prescribed semaglutide is extremely low. However, as with all medicines, patients and prescribers need to be aware of the symptoms of potential side-effects, even if the risk is very small, to ensure patients receive the appropriate treatment promptly should they occur.” — Dr. Alison Cave, MHRA Chief Safety Officer
- “ Samantha Mann, a consultant ophthalmologist and diabetic eye screening lead at the Royal College of Ophthalmologists, said: “This study relied on reported side-effects and so cannot prove causation or determine how common this problem truly is.” — Dr. Samantha Mann, Royal College of Ophthalmologists
- “A Novo Nordisk spokesperson said: “Patient safety is our top priority, and we take any reports about adverse events from the use of our medicines very seriously.” — Novo Nordisk Spokesperson
